Biodexa Pharmaceuticals Plc (BDRX) News
Follow Biodexa Pharmaceuticals Plc (BDRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 21 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Biodexa reports 100 patients enrolled in Serenta Phase 3 trial
Biodexa announced that 100 patients have enrolled in its registrational Phase 3 trial of Serenta in FAP.
EQUITY | Oct 13, 2026, 12:30 PM UTC
L
Biodexa Pharmaceuticals PLC (BDRX) Says eRapa Phase 3 Is Over 50% Enrolled; Futility Read in Q1 2027
Biodexa Pharmaceuticals PLC reported its Phase 3 eRapa trial in FAP is over 50% enrolled across 29 U.S./EU centers, with an interim futility analysis expected in Q1 2027. The program has FDA/EMA Orphan Drug status and $2
REGULATION | Sep 23, 2026, 10:33 AM UTC
L
The Longview: Fireside Chat with Biodexa CEO Stephen Stamp
Today's interview with Stephen Stamp, CEO of Biodexa Pharmaceuticals PLC NASDAQ:BDRX is about the Company's lead program, eRapa in Familial Adenomatous Polyposis (FAP), a genetic disease of the lower GI tract for which t
NEWS | Sep 23, 2026, 10:31 AM UTC
L
BDRX - The Longview: Fireside Chat with Biodexa CEO Stephen Stamp
BDRX - The Longview: Fireside Chat with Biodexa CEO Stephen Stamp
NEWS | Sep 23, 2026, 10:30 AM UTC
L
Biodexa Pharmaceuticals enters warrant exercise transaction for $2.3M gross proceeds; shares rise
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser
EQUITY | Sep 15, 2026, 12:31 PM UTC
L
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) Raises ~$2.3M Via Warrant Exercise, Issues New Warrants
Biodexa entered a warrant exercise agreement for ~$2.3M gross cash as an investor exercises 2,204,218 ADS warrants at $1.05. In return, Biodexa will issue new unregistered warrants for up to 4,408,436 ADSs at $1.05, exer
NEWS | Sep 15, 2026, 12:03 PM UTC
L
Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross ProceedsSeptember 15, 2026Biodexa Pharmaceuticals PLC, NASDAQ:BDRX (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company devel
NEWS | Sep 15, 2026, 12:03 PM UTC
L
BDRX - Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
BDRX - Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
NEWS | Sep 15, 2026, 12:00 PM UTC
L
Interim results for the six months ended June 30, 2026
September 11, 2026Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”)Interim results for the six months ended June 30, 2026Biodexa Pharmaceuticals PLC NASDAQ:BDRX, a clinical-stage biopharmaceutical company developin
NEWS | Sep 11, 2026, 08:32 PM UTC
L
BDRX - Interim results for the six months ended June 30, 2026
BDRX - Interim results for the six months ended June 30, 2026
NEWS | Sep 11, 2026, 08:30 PM UTC
L
Biodexa Pharmaceuticals expected to post breakeven results
Biodexa Pharmaceuticals PLC is expected to post breakeven results per share, according to an earnings preview.
EARNINGS | Sep 08, 2026, 11:01 AM UTC
L
JOYY rises in premarket after quarterly results
JOYY shares rose 3.6% in premarket trading after the company reported second-quarter earnings of $1.24 per share versus $1.28 expected and sales of $590.754 million versus $574.118 million expected.
EARNINGS | Aug 26, 2026, 09:22 AM UTC
M
Biodexa announces milestone in Serenta Phase 3 FAP trial
Biodexa announces a major milestone for its Serenta registrational Phase 3 trial in FAP, with no further details or catalyst supplied in the alert.
EQUITY | Aug 19, 2026, 12:30 PM UTC
L
BDRX Holds General Meeting
BDRX holds general meeting
EQUITY | Jul 29, 2026, 08:30 PM UTC
L
BDRX Initiates FAP Support in France
BDRX starts support for FAP patients
EQUITY | Jul 29, 2026, 12:30 PM UTC
L
BDRX Biodexa Pharmaceuticals - files for resale of 2.56M adss by selling shareholders - SEC filing
BDRX Biodexa Pharmaceuticals - files for resale of 2.56M adss by selling shareholders - SEC filing
REGULATION | Jul 15, 2026, 08:13 PM UTC
H
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Liminatus Pharma (NASDAQ: LIMN ) stock increased by 40.9% to $0.16 during Thursday's pre-market session. The market value of their outstanding shares is at $5.8 million. Stablecoin Development (AMEX: SDEV ) stock
EARNINGS | Jul 02, 2026, 12:05 PM UTC
H
Select Premarket Movers
Upside: -AVAV +35% (earnings, guidance) -VWAV +29% (acquires 51% controlling interest in private Israeli aerospace and defense company Meteor Aerospace for ~$20.4M in stock) -SEDG +11% (solar stock strength following FCC
GEOPOLITICS | Jun 30, 2026, 12:26 PM UTC
L
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Abivax (NASDAQ: ABVX ) shares increased by 36.0% to $130.74 during Tuesday's pre-market session. The company's market cap stands at $7.6 billion. Cuprina Holdings (Cayman) (NASDAQ: CUPR ) shares moved upwards by
EQUITY | Jun 30, 2026, 12:05 PM UTC
L
Biodexa Pharmaceuticals shares are trading lower after the company announced the pricing of its $3.5 million offering and concurrent private
Biodexa Pharmaceuticals shares are trading lower after the company announced the pricing of its $3.5 million offering and concurrent private placement of pre-funded warrants and warrants.
EQUITY | Jun 30, 2026, 12:04 PM UTC
L
Biodexa Prices $3.5M Offering And Concurrent Private Placement Of 282,952 Shares At $2.85/ADS.
Biodexa Prices $3.5M Offering And Concurrent Private Placement Of 282,952 Shares At $2.85/ADS.
EQUITY | Jun 30, 2026, 12:03 PM UTC